Name | Number of supported studies | Average coverage | |
---|---|---|---|
endothelial cell | 24 studies | 34% ± 15% | |
astrocyte | 17 studies | 40% ± 18% | |
oligodendrocyte precursor cell | 12 studies | 42% ± 18% | |
macrophage | 12 studies | 37% ± 16% | |
microglial cell | 12 studies | 41% ± 13% | |
oligodendrocyte | 12 studies | 41% ± 15% | |
fibroblast | 11 studies | 31% ± 13% | |
pericyte | 10 studies | 32% ± 15% | |
GABAergic neuron | 9 studies | 37% ± 18% | |
adipocyte | 9 studies | 33% ± 9% | |
smooth muscle cell | 9 studies | 27% ± 9% | |
epithelial cell | 8 studies | 38% ± 18% | |
T cell | 8 studies | 24% ± 8% | |
CD4-positive, alpha-beta T cell | 7 studies | 21% ± 5% | |
plasmacytoid dendritic cell | 7 studies | 22% ± 6% | |
dendritic cell | 7 studies | 33% ± 11% | |
mast cell | 7 studies | 26% ± 8% | |
glutamatergic neuron | 6 studies | 48% ± 22% | |
interneuron | 6 studies | 43% ± 18% | |
myeloid cell | 6 studies | 26% ± 6% | |
ciliated cell | 6 studies | 26% ± 9% | |
monocyte | 6 studies | 32% ± 8% | |
endothelial cell of lymphatic vessel | 6 studies | 34% ± 13% | |
neuron | 5 studies | 51% ± 20% | |
B cell | 5 studies | 26% ± 9% | |
CD8-positive, alpha-beta T cell | 5 studies | 21% ± 4% | |
cardiac muscle cell | 5 studies | 36% ± 9% | |
retinal cone cell | 5 studies | 28% ± 10% | |
natural killer cell | 5 studies | 27% ± 8% | |
club cell | 5 studies | 31% ± 12% | |
type I pneumocyte | 5 studies | 33% ± 9% | |
type II pneumocyte | 5 studies | 29% ± 7% | |
basal cell | 5 studies | 34% ± 21% | |
granule cell | 4 studies | 28% ± 8% | |
mesothelial cell | 4 studies | 28% ± 9% | |
lymphocyte | 4 studies | 39% ± 20% | |
Mueller cell | 4 studies | 37% ± 16% | |
amacrine cell | 4 studies | 36% ± 10% | |
retina horizontal cell | 4 studies | 35% ± 14% | |
retinal rod cell | 4 studies | 39% ± 8% | |
regulatory T cell | 4 studies | 19% ± 4% | |
CD16-positive, CD56-dim natural killer cell, human | 3 studies | 21% ± 6% | |
glial cell | 3 studies | 29% ± 10% | |
progenitor cell | 3 studies | 39% ± 10% | |
plasma cell | 3 studies | 33% ± 4% | |
effector memory CD8-positive, alpha-beta T cell | 3 studies | 23% ± 4% | |
vein endothelial cell | 3 studies | 35% ± 20% | |
GABAergic amacrine cell | 3 studies | 35% ± 12% | |
glycinergic amacrine cell | 3 studies | 36% ± 10% | |
endothelial cell of vascular tree | 3 studies | 36% ± 20% | |
hepatocyte | 3 studies | 39% ± 13% | |
retinal pigment epithelial cell | 3 studies | 39% ± 21% | |
abnormal cell | 3 studies | 33% ± 22% | |
ependymal cell | 3 studies | 46% ± 16% | |
alveolar macrophage | 3 studies | 35% ± 10% | |
capillary endothelial cell | 3 studies | 25% ± 6% | |
respiratory goblet cell | 3 studies | 35% ± 11% | |
goblet cell | 3 studies | 41% ± 30% | |
leukocyte | 3 studies | 47% ± 8% | |
transit amplifying cell | 3 studies | 41% ± 32% | |
mural cell | 3 studies | 39% ± 13% | |
mucus secreting cell | 3 studies | 29% ± 6% |
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
---|---|---|---|---|---|---|
esophagus | 100% | 2142.10 | 1445 / 1445 | 100% | 16.55 | 183 / 183 |
prostate | 100% | 2117.63 | 245 / 245 | 100% | 11.08 | 502 / 502 |
uterus | 100% | 2321.12 | 170 / 170 | 100% | 10.39 | 458 / 459 |
lung | 100% | 2273.60 | 578 / 578 | 100% | 10.75 | 1152 / 1155 |
breast | 100% | 2144.76 | 459 / 459 | 100% | 17.43 | 1115 / 1118 |
thymus | 100% | 2290.26 | 653 / 653 | 100% | 10.65 | 603 / 605 |
ovary | 100% | 2369.98 | 180 / 180 | 100% | 12.37 | 428 / 430 |
intestine | 100% | 2024.69 | 966 / 966 | 99% | 8.93 | 524 / 527 |
bladder | 100% | 2067.95 | 21 / 21 | 99% | 8.92 | 500 / 504 |
pancreas | 100% | 1203.92 | 328 / 328 | 99% | 8.42 | 176 / 178 |
brain | 99% | 1064.68 | 2608 / 2642 | 100% | 9.92 | 705 / 705 |
stomach | 100% | 1532.13 | 359 / 359 | 99% | 11.45 | 282 / 286 |
kidney | 100% | 1259.37 | 89 / 89 | 98% | 9.49 | 885 / 901 |
adrenal gland | 100% | 1605.29 | 258 / 258 | 98% | 6.50 | 225 / 230 |
skin | 100% | 2560.70 | 1809 / 1809 | 96% | 8.58 | 451 / 472 |
liver | 100% | 742.22 | 225 / 226 | 73% | 3.53 | 298 / 406 |
adipose | 100% | 1891.46 | 1204 / 1204 | 0% | 0 | 0 / 0 |
blood vessel | 100% | 2041.29 | 1335 / 1335 | 0% | 0 | 0 / 0 |
lymph node | 0% | 0 | 0 / 0 | 100% | 6.19 | 29 / 29 |
spleen | 100% | 1833.56 | 241 / 241 | 0% | 0 | 0 / 0 |
tonsil | 0% | 0 | 0 / 0 | 100% | 12.50 | 45 / 45 |
ureter | 0% | 0 | 0 / 0 | 100% | 4.65 | 1 / 1 |
muscle | 100% | 1157.70 | 801 / 803 | 0% | 0 | 0 / 0 |
heart | 98% | 1127.64 | 845 / 861 | 0% | 0 | 0 / 0 |
peripheral blood | 89% | 1145.24 | 825 / 929 | 0% | 0 | 0 / 0 |
eye | 0% | 0 | 0 / 0 | 85% | 4.86 | 68 / 80 |
abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
GO_0008285 | Biological process | negative regulation of cell population proliferation |
GO_0030071 | Biological process | regulation of mitotic metaphase/anaphase transition |
GO_0048568 | Biological process | embryonic organ development |
GO_0045582 | Biological process | positive regulation of T cell differentiation |
GO_0006357 | Biological process | regulation of transcription by RNA polymerase II |
GO_2000045 | Biological process | regulation of G1/S transition of mitotic cell cycle |
GO_0045663 | Biological process | positive regulation of myoblast differentiation |
GO_0006338 | Biological process | chromatin remodeling |
GO_0060038 | Biological process | cardiac muscle cell proliferation |
GO_0070316 | Biological process | regulation of G0 to G1 transition |
GO_0045597 | Biological process | positive regulation of cell differentiation |
GO_1905168 | Biological process | positive regulation of double-strand break repair via homologous recombination |
GO_2000819 | Biological process | regulation of nucleotide-excision repair |
GO_0060982 | Biological process | coronary artery morphogenesis |
GO_0042592 | Biological process | homeostatic process |
GO_0030336 | Biological process | negative regulation of cell migration |
GO_0006337 | Biological process | nucleosome disassembly |
GO_2000781 | Biological process | positive regulation of double-strand break repair |
GO_0003007 | Biological process | heart morphogenesis |
GO_0005886 | Cellular component | plasma membrane |
GO_0000776 | Cellular component | kinetochore |
GO_0016514 | Cellular component | SWI/SNF complex |
GO_0005654 | Cellular component | nucleoplasm |
GO_0016363 | Cellular component | nuclear matrix |
GO_0016586 | Cellular component | RSC-type complex |
GO_0000785 | Cellular component | chromatin |
GO_0003677 | Molecular function | DNA binding |
GO_0046872 | Molecular function | metal ion binding |
GO_0005515 | Molecular function | protein binding |
Gene name | ARID2 |
Protein name | AT rich interactive domain 2 (ARID, RFX-like), isoform CRA_d (AT-rich interaction domain 2) ARID2 protein AT-rich interactive domain-containing protein 2 (ARID domain-containing protein 2) (BRG1-associated factor 200) (BAF200) (Zinc finger protein with activation potential) (Zipzap/p200) AT-rich interaction domain 2 |
Synonyms | KIAA1557 BAF200 hCG_1998145 |
Description | FUNCTION: Involved in transcriptional activation and repression of select genes by chromatin remodeling (alteration of DNA-nucleosome topology). Required for the stability of the SWI/SNF chromatin remodeling complex SWI/SNF-B (PBAF). May be involved in targeting the complex to different genes. May be involved in regulating transcriptional activation of cardiac genes. . |
Accessions | ENST00000479608.5 F8WCU9 F8VWP4 Q4G0S8 Q8WV72 ENST00000444670.5 ENST00000422737.7 A0A087WY37 ENST00000477947.1 A0A8V8TP93 ENST00000457135.2 Q68CP9 F8W108 ENST00000334344.11 [Q68CP9-1] |